please check out the anti-mandate news »

« prev   random   next »


Study Finds No Benefit from Drug Touted by Trump

By rdm follow rdm   2020 Apr 21, 10:35am 451 views   4 comments   watch   nsfw   quote   share    

Just one study, but they did have a control group.

“A malaria drug widely touted by President Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals,” the AP reports.

“There were more deaths among those given hydroxychloroquine versus standard care, researchers reported.”
1   Tenpoundbass   ignore (16)   2020 Apr 21, 10:58am     ↓ dislike (0)   quote   flag      

I don't fucking care, I'll take my chances.

Doctor Frauduci has no right to shit on a FDA approved drug being prescribed by actual "Doctors" which he is not, he's the regional salesman for "Fred's Vaccine Emporium."

We'll see what the email dumps turn up, shits about to hit the fan for Bill Gates, Dr Frauduci and The Who Voodoo Commie Dictator.

That study does not align with actual clinical cases.
3   MisdemeanorRebel   ignore (3)   2020 Apr 21, 11:03am     ↓ dislike (0)   quote   flag      

Tenpoundbass says
That study does not align with actual clinical cases.

It doesn't. I skimmed and we don't know the severity of the cases; in other words, I suspect those given the HC/HC+AZ had more severe cases (and more underlying conditions) than those who weren't. Also, they do admit in the retrospective - they searched a database - that the majority are Black, and you have the cell shape differential issue and a population more prone to heart ailments than the average person.
4   MisdemeanorRebel   ignore (3)   2020 Apr 28, 7:23pm     ↓ dislike (0)   quote   flag      

TUSCON, Ariz., April 28, 2020 (GLOBE NEWSWIRE) -- In a letter to Gov. Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil®).

To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS, in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.

The antiviral properties of these drugs have been studied since 2003. Particularly when combined with zinc, they hinder viral entry into cells and inhibit replication. They may also prevent overreaction by the immune system, which causes the cytokine storm responsible for much of the damage in severe cases, explains AAPS. HCQ is often very helpful in treating autoimmune diseases such as lupus and rheumatoid arthritis.

Additional benefits shown in some studies, AAPS states, is to decrease the number of days when a patient is contagious, reduce the need for ventilators, and shorten the time to clinical recovery.

Peer-reviewed studies published from January through April 20, 2020, provide clear and convincing evidence that HCQ may be beneficial in COVID-19, especially when used early, states AAPS. Unfortunately, although it is perfectly legal to prescribe drugs for new indications not on the label, the Food and Drug Administration (FDA) has said that CQ and HCQ should be used for COVID-19 only in hospitalized patients in the setting of a clinical study if available. Most states are making it difficult for physicians to prescribe or pharmacists to dispense these medications.

As the letter to Gov. Ducey notes, “Many nations, including Turkey and India, are protecting medical workers and contacts of infected persons prophylactically. According to, deaths per million persons from COVID-19 as of Apr 27 are 167 in the U.S., 33 in Turkey, and 0.6 in India.”

about   best comments   contact   one year ago   suggestions